Related references
Note: Only part of the references are listed.A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B
Vincent Rijckborst et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2009)
Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a
Patrick Marcellin et al.
GASTROENTEROLOGY (2009)
Early Serum HBsAg Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in HBeAg-Negative Patients
Rami Moucari et al.
HEPATOLOGY (2009)
Hepatitis B Virus Surface Antigen Levels: A Guide to Sustained Response to peginterferon alfa-2a in HBeAg-Negative Chronic Hepatitis B
Maurizia Rossana Brunetto et al.
HEPATOLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Patrick Marcellin et al.
JOURNAL OF HEPATOLOGY (2009)
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy
Daniel Shouval et al.
JOURNAL OF HEPATOLOGY (2009)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
Yun-Fan Liaw et al.
HEPATOLOGY INTERNATIONAL (2008)
Treatment predictors of a sustained virologic response in hepatitis B and C
Annika Kau et al.
JOURNAL OF HEPATOLOGY (2008)
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Patrick Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Drug therapy - Hepatitis B virus infection
Jules L. Dienstag
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years
G. Fattovich et al.
GUT (2008)
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B
Robert G. Gish et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
F. Bonino et al.
GUT (2007)
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
Karsten Wursthorn et al.
HEPATOLOGY (2006)
Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response
Martijn J. ter Borg et al.
HEPATOLOGY (2006)
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
CL Lai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
UH Iloeje et al.
GASTROENTEROLOGY (2006)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Response to interferon alfa is hepatitis B virus genotype dependent:: genotype A is more sensitive to interferon than genotype D
A Erhardt et al.
GUT (2005)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
SJ Hadziyannis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
GKK Lau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay
M Deguchi et al.
JOURNAL OF VIROLOGICAL METHODS (2004)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
P Marcellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
B Werle-Lapostolle et al.
GASTROENTEROLOGY (2004)
Methods for categorizing a prognostic variable in a multivariable setting
M Mazumdar et al.
STATISTICS IN MEDICINE (2003)
World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants
ML Funk et al.
JOURNAL OF VIRAL HEPATITIS (2002)
Hepatitis B e antigen-negative chronic hepatitis B
SJ Hadziyannis et al.
HEPATOLOGY (2001)
Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
T Santantonio et al.
JOURNAL OF HEPATOLOGY (2000)
Share Paper
